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Abstract: Background: Dual diagnosis (DD), defined as the co-occurrence of a substance use disorder (SUD) and a 
severe mental illness (SMI), is associated with several negative outcomes. Typical antipsychotics (TAP) are not of great 
value for patients with DD as they are associated with poorer responses and can worsen SUD. Atypical antipsychotics 
(AAP) offer several advantages compared to TAP and in DD patients they have been found to be effective in treating 
both, psychiatric symptoms and substance use. The aim of this article is to review the use of clozapine (CLO) for treating 
DD patients. 
Methods: A search of MEDLINE, EMBASE and Pubmed was performed in order to identify publications that examined 
the use of CLO in the treatment of DD.  
Results: There is consistent data in regard to the efficacy of CLO in the treatment of DD patients in both studies with and 
without comparison to TAP and other AAP. These positive results have been found for different substances of abuse and 
in different SMI. However, there is a lack of randomized, placebo-controlled trials in this field. 
Conclusions: CLO has been found to be at least as effective as TAP and other AAP in treating psychiatric symptoms, but 
it has shown itself to be more effective in reducing substance use in DD patients. Several hypotheses have been 
proposed to explain this effectiveness: 1) amelioration of reward system dysfunction in the dopamine-mediated 
mesocorticolimbic circuits; 2) improvement of negative symptoms, and relief of anxiety, depression and dysphoria; 3) 
improvement of cognitive dysfunction associated with DD; and 4) reduction of craving. CLO might be considered as a 
pharmacological agent for use in patients with DD, although safety issues, such as the risk of agranulocytosis and 
seizures must be taken into account. Even though there is a growing body of evidence suggesting the beneficial effects 
of CLO in DD patients, further randomized, blind, controlled trials, with larger sample sizes and longer follows-up are 
needed. 
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INTRODUCTION 
Dual diagnosis (DD) is traditionally defined as the 
co-occurrence of a substance use disorder (SUD) and 
a severe mental illness (SMI) [1]. Although in recent 
years the concept of DD has been extended and is 
being used to define the co-occurrence of any mental 
illness and a SUD, in this review we will consider 
schizophrenia and related disorders, with concomitant 
SUD. 
It is estimated that more than 50% of the patients 
with a psychiatric disorder meet DSM-IV criteria for  
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alcohol and/or substance abuse and/or dependence 
[2]. The substances most commonly used by these 
patients are alcohol, followed by cannabis and cocaine 
[3]. The demographic correlates of substance use are 
well documented and people with SMI that have 
concomitant SUD tend to be younger men, with a lower 
educational level, a family history of SUD, and 
comorbidity with a behaviour disorder such as an 
antisocial personality disorder (ASPD) [4]. 
Several hypotheses have been used to explain the 
co morbidity between SMI and SUD. Traditionally, the 
association between substance abuse and SMI was 
explained by the “self-medication” theory, which stated 
that patients used substances to relieve psychiatric 
symptoms or the side-effects of psychiatric medication 
[5]. However, in recent years, the neurobiological 
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theory proposed by Green et al. (1999) is gaining 
importance in the field of DD. They suggest that there 
is a “reward deficiency syndrome” in people with SMI, 
so they have a dysfunction in their dopamine (DA)-
mediated mesocorticolimbic (MCL) reward pathways, 
and they use alcohol and other drugs of abuse in order 
to ameliorate this dysfunction in the brain reward 
system [6]. 
Comorbid SUD among patients with SMI is 
associated with more negative outcomes such as poor 
response to treatments [7], more relapses [8], more 
admissions to hospital [9], non-compliance with 
treatment [10], increased rates of suicidal ideation [11], 
increased rates of impulsive and violent behaviours 
[12], increased rates of neurological and psychiatric 
symptoms [13], and increased rates of poverty, 
unemployment and social exclusion [14]. 
Typical antipsychotics (TAP), unfortunately, are 
often not of great value for patients with a SMI and a 
SUD. In fact, a poorer response to TAP has been 
described in patients with a past history of SUD [15, 16] 
and even an increase in number of cigarettes smoked 
after the initiation of haloperidol (HAL) treatment [17]. 
Two main hypotheses have been proposed to explain 
this lack of efficacy of TAP in DD patients: 1) TAP are 
associated with considerable side effects and it has 
been postulated that patients with the co-occurrence of 
a SMI and a SUD may use substances to “self-
medicate” side-effects produced by TAP, such as extra 
pyramidal side-effects (EPS) and dysphoria [18-20] and 
2) they worsen the functioning of DA-mediated MCL 
brain reward circuits because of a potent D2 receptor 
blockade action [6, 21].  
Atypical antipsychotics (AAP) offer several 
advantages over TAP: 1) they are effective in treating 
positive symptoms to the same extent as TAP; 2) they 
are as effective or superior to TAP in treating negative 
symptoms; 3) they exert antidepressant and mood 
stabilization actions; 4) they are effective in treating 
aggression and impulsivity; 5) they exhibit better 
tolerability, especially in terms of decreased EPS, 
tardive dyskinesia and hyperprolactinemia; 6) they 
diminish suicidality; and 7) they are associated with an 
improvement in cognition. They have been reported to 
offer some advantages in the treatment of SUD 
probably due to their mechanism of action, which 
includes less DA antagonism and pharmacological 
action on serotonin (5-HT), histamine (HIS), and 
norepinephrine (NE) pathways [22, 23]. 
CLO is considered to be the “prototypical” AAP and 
has one of the most complex pharmacological profiles 
of all the AAP. It produces weak blockade of D2 
receptor and potent blockade of the serotonergic 5-
HT2A and the NA 1 and 2 receptors, and it 
ameliorates the deficits in both the mesocortical and 
mesolimbic DA neuronal projections [24]. Although it 
has been considered the “gold standard” for the 
treatment of schizophrenia and related disorders, in 
clinical practice CLO is not used as a first-line 
treatment due to several undesirable side effects 
including the risk of agranulocytosis and seizures, and 
the consequent need for regular blood draws to assess 
blood abnormalities [25].  
The aim of this article is to review the use of CLO 
for treating DD, in order to critically discuss its 
effectiveness both in treating the psychiatric disorder 
and the SUD, its tolerability and safety. 
METHODS 
A search of MEDLINE (1980-present), EMBASE 
(1980-present) and Pubmed (1980-present) was 
performed in order to identify English- and Spanish-
language publications that examined the use of CLO in 
the treatment of DD. Major search terms included dual 
diagnosis, schizophrenia, schizoaffective disorder, 
bipolar disorder, SUD, on one hand, and AAP and CLO 
on the other. 
RESULTS 
Clozapine (CLO) is the AAP with the greatest body 
of research regarding its use as a pharmacological 
agent for patients with DD. Several case reports, case 
series, retrospective studies and prospective studies 
have suggested that CLO may decrease the use of 
nicotine, alcohol, or other drugs of abuse among 
patients with DD.  
Regarding nicotine, retrospective and cross-
sectional studies have found an overall decrease in 
smoking [26, 27] and less smoking compared with DD 
patients taking TAP [28-31] or risperidone (RIS) [32]. 
McEvoy reported a decrease in the drive to smoke in 8 
out of 10 treatment-resistant schizophrenic (TR-SCH) 
smoker patients after 12 weeks of CLO treatment [26]. 
Subsequently, another group reported that 11 out of 13 
schizophrenic patients, eight of whom had a history of 
another SUD [alcohol (n=6), cannabis (n=6), cocaine 
(n=2), heroin (n=1), hallucinogens (n=2)], reduced or 
stopped smoking after taking CLO. These patients did 
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not associate their decrease in smoking with a 
reduction in cigarette craving, rather they attributed it to 
an improvement in their ability to plan and budget, as 
well as becoming more concerned about the cost of 
cigarettes and physical health [27]. Switching from HAL 
to CLO (plasmatic levels 1200 ng/ml) was associated 
with a reduction of 25-35% in smoking in a sample of 
12 schizophrenic patients [28]. In addition, these 
results were supported by two studies in which 
switching from TAP to CLO was associated with a 
significant (p=0.025) decrease in the daily amount of 
cigarettes smoked in a sample of 18 schizophrenic 
patients and comorbid nicotine dependence (ND) [30], 
and in a sample of 55 smokers of a total of 70 TR-SCH 
patients [29]. It was also reported that smokers had a 
greater therapeutic response to CLO compared to non-
smokers [29]. More recently, a retrospective study in 
which hospitalized, schizophrenic patients who were 
divided into three treatment groups: TAP (n=15), CLO 
(n=6) or other AAP (n=16), found that smoking 
prevalence differed significantly among the three 
treatment groups (p<0.001), CLO being the 
pharmacological agent that was associated with a 
significantly lower incidence of smoking compared to 
TAP (p<0.03) or other AAP (p=0.042) [33]. Finally, a 
Canadian group has conducted two small studies 
switching from depot TAP to CLO [31] and adding CLO 
to RIS [32]. In both studies it was demonstrated that 
patients receiving treatment with CLO smoked less, as 
they showed significantly lower levels of expired carbon 
monoxide (CO) (p<0.01 and p=0.03, respectively) and 
significantly less self-reported smoking, assessed by 
the Fagerstrom Test for Nicotine Dependence (FTND) 
(p=0.08 and p=0.04, respectively) as compared to 
patients on depot TAP or RIS alone.  
Regarding alcohol and other substances of abuse, a 
series of case reports and case series studies 
beginning in the mid-1990s, suggested that CLO was 
effective in patients with a co-occurring SMI and SUD, 
and that it appeared to reduce substance use. The first 
to report on the effectiveness of CLO in treating 
patients with a DD were Yovell and Opler (1994). They 
reported the case of a 37-year-old male diagnosed with 
Schizoaffective Disorder (SAD) and comorbid Cocaine 
Dependence (COD) who showed a reduction in 
psychotic symptoms, an improvement in social 
functioning and a reduction in cocaine craving and 
craving for other substances after CLO at doses of 600 
mg/day was initiated [34]. Concurrently, CLO (500 
mg/day, up to 6 months) was also found to be effective 
in decreasing psychotic symptoms and, in turn, 
abstinence from alcohol, in two 40-year-old males with 
TR-SCH and chronic alcohol abuse (AA) [35]. In 
addition, CLO was effective in preventing relapse in 
alcohol or drug use in a TR-SCH patient with poly-drug 
abuse (PDA) [36]. Finally, the psychotic symptoms of a 
patient with a TR-SCH and comorbid alcohol (AA) and 
cocaine (COA) abuse were stabilized and the patient 
remained abstinent from alcohol and cocaine use after 
initiating CLO at dosages of 550 mg/day [37].There are 
also two recent case reports in which augmentation 
strategies for CLO have been proposed for treating 
schizophrenic patients with comorbid Alcohol Use 
Disorders (AUD). In the first one, three TR-SCH 
patients with a concomitant alcohol dependence (AD) 
were successfully treated adding lamotrigine (LAM) 
(200-300 mg/day) to their previous treatment with CLO 
(300-600 mg/day), and such treatment led to the 
improvement of the psychopathology and significantly 
reduced craving (p<0.05) [38]. In the second one, a 47-
year-old schizophrenic male with severe, comorbid 
alcohol dependence was treated effectively when 
amisulpride (AMS) (600 mg/day) was added to his 
treatment with CLO (600-1200 mg/day), improving his 
resistant schizophrenia symptoms and behaviour in 
relation to alcohol [39].  
Results of case reports have been consolidated in 
several retrospective and naturalistic studies where 
CLO has also been found to be effective for treating 
patients with a SMI and a comorbid SUD. In a 
retrospective survey that included 58 patients 
diagnosed with schizophrenia or SAD and a comorbid 
SUD [alcohol (20%), cannabis (3%), cocaine (13%) 
and PSA (24%)], it was found that more than 85% of 36 
patients who initiated treatment with CLO decreased 
their alcohol and substance consumption, and 72% of 
them achieved abstinence. In addition, of those 
patients who were not actively using substances at the 
beginning of the study none restarted substance use. 
Moreover, in those patients that remained in treatment, 
the reduction of substance use significantly correlated 
with an improvement in global clinical symptoms 
(p=0.002) [40]. These results were extended in a 3-
year-follow-up-naturalistic study in which 151 patients 
with schizophrenia or SAD with a comorbid alcohol 
(69.5%) or other SUD [cannabis (31.8%) and cocaine 
(11.3%)] were included. Among 36 patients switched to 
CLO, significant improvement was described in 
substance abuse stage (p=0.003), and the severity of 
alcohol (p=0.004) and drug (p=0.0001) use, and the 
number of drinking days (p=0.0002) and days of drug 
abuse (p=0.0003) significantly decreased. At the end of 
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the study, 79% of the patients receiving CLO were in 
remission from their AUD compared to 33.7% of 
patients who were not on CLO (p=0.001), and 65% of 
patients receiving CLO were in remission from the 
SUD, compared to only 29.6% of patients not taking 
CLO (p=0.032). The relationship between a greater 
length of time on CLO and the likelihood of remission of 
SUD at 3-year follow-up tend toward significance for 
alcohol (p=0.07), but not for other drugs (p=ns). 
Improvement in alcohol and substances of abuse 
parameters was associated with an improvement in 
psychopathology, especially regarding symptoms of 
anergia (p=0.002), but not symptoms of thought 
disorder (p=ns) [41].  
In comparative studies, CLO has been shown to be 
more effective than TAP and other AAP in treating 
patients with a concomitant SMI and SUD. Regarding 
TAP, in a retrospective study that included 204 patients 
with a schizophrenic spectrum disorder (SSD) the rates 
of concurrent SUD decreased from 57% to none in the 
35 patients taking CLO, whereas they decreased from 
50% to 13% among the 169 patients taking TAP, 
suggesting that CLO was more effective in treating 
SUD [42]. In addition, very recently, a 3-month 
treatment with CLO has been compared with a 3-month 
treatment with TAP in an experimental study in which 
43 patients diagnosed with SCH or SAD and a 
concomitant SUD including AA (42% CLO, 69% TAP), 
AD (25% CLO, 15% TAP), cannabis abuse (CAA) 
(33% CLO, 46% TAP), cannabis dependence (CAD) 
(25% CLO, 15% TAP), poly substance dependence 
(PSD) (25% CLO, 23% TAP), cocaine abuse (COA) 
(8% CLO, 15% TAP), COD (8% CLO, 8% TAP), heroin 
abuse (HA) (8% CLO), hallucinogen abuse (8% TAP) 
and inhalant abuse (8% TAP), were tested with an 
odour hedonic task. They found that CLO, compared to 
TAP, was significantly (p=0.01) associated with a 
broader and stronger experience of rewarding olfactory 
stimuli and, subsequently, it could ameliorate the 
dysfunction of the brain reward system of patients with 
DD, thus reducing their substance abuse [25]. 
Regarding other AAP, in a retrospective study which 
included 41 patients with schizophrenia or SAD and 
comorbid alcohol and/or cannabis use disorders 
treated with either RIS (n=8) or CLO (n=33) for at least 
one year, abstinence rates were significantly higher in 
patients treated with CLO than in those treated with 
RIS (54% vs. 13%, p=0.05) [43]. In addition, in a 2-year 
prospective, naturalistic, observational study, which 
included 61 patients with schizophrenia and AUD, 
cases receiving CLO (n=25) or RIS (n=36) were 
analysed, and it was found that at the end of the study, 
patients treated with CLO were readmitted to hospital 
significantly later than the RIS treated group (p=0.045). 
Also at the end of the study 75% of the RIS treated 
patients had been admitted to the hospital compared to 
only 48% of the CLO treated patients [44]. More 
recently, two studies have explored the use of CLO in 
DD patients with comorbid cannabis use disorders 
(CAUD), comparing it to RIS and OLZ on one hand 
[45], and to ziprasidone (ZIP) on the other [46]. The 
first study that was a multisite, longitudinal, naturalistic 
cohort study which included 123 patients who met 
criteria for a non-affective psychotic disorder and a 
concomitant CAD, found that there was significantly 
less cannabis craving (p=0.001), assessed by the 
Obsessive Compulsive Drug Use Scale (OCDUS) 
cannabis specific version (OCDUS-CAN), in patients 
treated with CLO (mean dosage 350 mg/day) (n=23) 
compared to patients treated with RIS (mean dosage 
3.46 mg/day) (n=48), although significant differences 
between CLO and OLZ (mean dosage 13.78 mg/day) 
(n=52) in craving were not found [45]. The second one 
was a 12-month, randomized, controlled trial in which 
30 patients with SCH and comorbid CAUD were 
randomized to receive either CLO (n=14) (50-425 
mg/day, mean dosage 225 mg/day) or ZIP (n=16) (80-
400 mg/day, mean dosage 200 mg/day). Both, CLO 
and ZIP were equally effective in reducing the 
frequency of cannabis use during follow-up. The 
reduction of cannabis use was already seen at the 3-
month follow-up examination and was stable over the 
period of the 12 months. However, regarding psychotic 
symptoms, there was a stronger decline in positive 
symptoms in patients treated with CLO (p=0.05). 
Despite these positive results, CLO was also 
associated with significantly more side effects, 
especially hyper salivation (p=0.017) and overall poorer 
compliance with treatment (p=0.024). Some of these 
CLO side effects such as sedation were reported to 
help diminish craving in some patients. The fact that 
this study used lower dosages of CLO compared to the 
previous ones, could have explained the non-
superiority of CLO compared to ZIP [46]. All these 
results have been replicated in a prospective, 10-year 
follow-up study with a sample of 223 outpatients, of 
whom 95 met criteria for schizophrenia or SAD and 
experienced a 6-month remission from their SUD. 
There were three treatment groups: TAP (n=62), CLO 
(n=25) or other AAP (n=8). Patients taking CLO, at a 
mean dose of 417 mg/day, were significantly less likely 
to experience substance abuse relapse 1 year after 
remission (p=0.003) and 2 years after remission 
(p=0.05) [47].  
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Table 1: Clinical Studies with Clozapine on Dual Diagnosis 
Author 
Nº patients 
Design; Duration; 
Intervention 
Outcomes Results 
Yovell and Opler 
(1994) 
N=1 
CR 
4 weeks 
SAD + COA and poly-substance 
use 
CLO (600 mg/d) 
Psychotic symptoms 
Social functioning 
Cocaine use and craving 
Reduction of psychopathology and cocaine use 
 
Albanese et al. 
(1994) 
N=2 
CR 
Up to 6 months 
TR-SCH + AUD and poly-
substance use 
CLO (500 mg/d) 
Psychotic symptoms 
Alcohol use 
Reduction of psychopathology and alcohol 
abstinence after switching from TAP 
Buckley et al. 
(1994) 
N=118 
Ret, OL 
6 months 
TR-SCH or TR-SAD, 29 with 
comorbid SUD 
Alcohol (11%) 
CLO (dose N.S.) 
Psychotic symptoms and 
psychosocial functioning 
Similar improvement in psychopathology and 
psychosocial functioning in patients with SUD and 
without SUD 
Reduction of substance use and craving 
Marcus and Snyder 
(1995) 
N=16 
CS 
Duration N.S. 
SCH, 13 with ND, 8 with another 
SUD: Alcohol (n=8), Cannabis 
(n=6), Cocaine (n=2), Heroine 
(n=1), Hallucinogens (n=1) 
CLO (dose N.S.) 
Smoking reduction or 
cessation 
Psychotic symptoms 
Smoking reduction or cessation in 11 out of 13 
patients. Improvement in psychotic symptoms  
McEvoy et al. 
(1995) 
N=12 
Nat study 
12 week 
SCH + ND 
CLO (dose N.S.) 
Smoking reduction 25-35% decrease in smoking 
George et al. 
(1995) 
N=29 
Ret study 
N.S. 
SCH + ND 
CLO (dose N.S.) 
Smoking reduction Smoking reduction in all the patients (p=0.025) 
Buckley (1998) 
N=1 
CR 
3 years 
TR-SCH + poly- substance use 
(alcohol, cannabis and cocaine) 
CLO (dose N.S.) 
Relapse in drug abuse No relapse of alcohol and drug use under CLO 
treatment 
Lee et al. (1998) 
N=204 
Ret study 
N.S. 
SCH + SUD 
CLO (n=35) or TAP (n=169) 
% of reduction of SU 57% to none in SU in the CLO group and from 
50% to 13% in the other group 
McEvoy et al. 
(1999) 
N=70 
Nat study 
12 weeks 
TR-SCH, 55 smokers 
CLO (dose N.S) 
Response to CLO 
Smoking reduction 
Smokers showed a greater response to CLO. They 
smoked less under treatment with CLO compared 
to treatment with TAP 
Tsuang et al. 
(1999) 
N=1 
CR 
N.S. 
TR-SCH + COUD and AUD 
CLO (550 mg/d) 
Psychotic symptoms 
Alcohol and cocaine use 
Psychiatrically stable and abstinent from alcohol 
and cocaine after switching to CLO 
Volavka et al. 
(1999) 
N=331 
Ret study 
6 months 
SCH or SAD +/- SUD 
CLO (dose N.S.) 
Psychopathology and 
psychosocial functioning 
Similar improvement in psychopathology and 
psychosocial functioning in substance abusers and 
non-substance abusers 
 
Combs and 
Advokat (2000) 
N=39 
Nat study 
Duration N.S. 
SCH or SAD + ND 
TAP (n=15) or CLO (n=6) or 
other AAP (n=18) 
Smoking behaviour (Self-
reports and Observer-
reports) 
Psychopathology (BPRS) 
Cognitive abilities (WAIS) 
Side effects (AIMS) 
Smoking prevalence differed significantly among 
the three groups (p<0.001). CLO was associated 
with a significantly lower incidence of smoking than 
either TAP (P<0.003) or other AAP (p=0.042) 
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(Table 1): Continued. 
Author 
Nº patients 
Design; Duration; 
Intervention 
Outcomes Results 
Drake et al. (2000) 
N=151 
Pros, OL, Ret analysis of 
subgroups 
3 years 
SCH or SAD + AUD or SUD 
CLO (n=36) or non-CLO (n=115) 
(dose N.S.) 
Alcohol and substance 
use, and days of alcohol 
use and drug use (TLFB, 
UTS, AUS, DUS, SATS) 
Psychopathology (BPRS)  
CLO was associated with a significant 
improvement of substance abuse stage (p=0.003), 
and a decrease in the severity of alcohol (p=0.004) 
and drug (p=0.0001) use, and the number of 
drinking days (p=0.0002) and days of drug abuse 
(p=0.0003). 79% of patients receiving CLO were in 
remission from their AUD compared to 33.7% of 
patients who were not on CLO (p=0.001), and 65% 
of patients receiving CLO were in remission from 
the SUD, compared to 29.6% of patients not taking 
CLO (p=0.032) 
Zimmet et al. 
(2000) 
N=58 
Ret, OL study 
Over 3 years 
SCH or SAD + SUD 
CLO (dosage N.S.) 
Psychotic symptoms 
Substance Use 
More than 85% of patients on CLO decreased their 
alcohol and substance consumption, 72% of them 
achieving abstinence. The reduction of substance 
use significantly correlated with an improvement in 
global clinical symptoms (p=0.002) 
Procyshyn et al. 
(2001) 
N=N.S. 
Cross Sectional 
Duration N.S. 
SCH + ND 
CLO or Depot TAP 
Self-reported smoking 
(FTND) 
Expired CO 
Significant reduction in expired CO (p<0.01) and a 
trend toward significance in self-reported smoking 
(p=0.08) in patients taking CLO compared to 
patients taking Depot TAP 
Procyshyn et al. 
(2002) 
N=14 
Cross Sectional 
Duration N.S. 
SCH + ND 
RIS alone or RIS and CLO 
Self-reported smoking 
(FTND)) 
Expired CO 
 
Significant reduction in expired CO (p=0.03) and in 
self-reported smoking (p=0.04) in patients taking 
CLO and RIS compared to patients taking RIS 
alone 
Green et al. (2003) 
N=41 
Ret study 
1 year 
SCH or SAD + AUD or CAUD 
CLO (n=33) (mean dose 439.6 
mg/d) or RIS (n=8) (mean dose 
3.9 mg/d) 
Alcohol/Cannabis use 
Abstinence rates 
Abstinence rates were significantly higher in 
patients treated with CLO (54%) than in those 
treated with RIS (13%) (p=0.05) 
Kelly et al. (2003) 
N=45 
OL 
5 years 
TR-SCH, 19 with comorbid SUD 
Psychopathology 
Readmission rates 
Better treatment response in patients with 
comorbid SUD. Similar rates of readmission at 1-
year follow-up 
Kalyoncu et al. 
(2005) 
N=3 
CS 
TR-SCH + AUD 
CLO + LAM 
Alcohol consumption 
Alcohol craving (OCDS) 
CLO + LAM was effective in treating AD 
A significant reduction in alcohol craving was 
observed (p<0.05) 
Brunette et al. 
(2006) 
N=95 
Pros, follow-up study 
10 years 
SCH or SAD + SUD, 6-month 
abstinence 
Alcohol (74.8%), other drugs 
(41.9%) 
CLO (mean dosage 484 mg/d) 
(n=25) or TAP (n=62) or other 
AAP (n=8) 
Relapse rates at 1 and 2-
year follow-up 
Significantly less substance abuse relapse with 
CLO compared to TAP and other AAP at 1-year 
(p=0.003) and 2-year follow-up (p=0.05) 
Dervaux and Cazali 
(2007) 
N=1 
 
CR 
Over 25 months 
SCH + AD 
CLO (600-1200 mg/d) + AMS 
(600 mg/d) 
Psychopathology 
Addictive behaviour 
regarding alcohol 
CLO + AMS was effective in controlling psychiatric 
symptoms and addictive behaviour regarding 
alcohol 
Kim et al. (2008) 
N=61 
Pros, Nat, Obs 
2 years 
SCH + AUD 
CLO (mean dosage 423.6 mg/d) 
(n=25) or RIS (mean dosage 7.6 
mg/d) (n=36) 
Hospitalization rates 
Time until hospitalization 
CLO treated patients were readmitted to hospital 
significantly later than the RIS treated patients 
(p=0.045). At the end of the study, 75% of the RIS 
treated patients had been admitted to hospital, 
compared to 48% of patients treated with CLO 
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 (Table 1): Continued. 
Author 
Nº patients 
Design; Duration; 
Intervention 
Outcomes Results 
Machielsen et al. 
(2012) 
N=123 
MC, Long, Nat study 
6 years 
SCH, SCHD, SAD, DelD or 
PDNOS + CAD 
CLO (mean dosage 350 mg/d) 
(n=23) or RIS (mean dosage 
3.46 mg/d) (n=48) or OLZ (mean 
dosage 13.78 mg/d) (n=52) 
Cannabis craving 
(OCDUS-CAN) 
There were significant differences in craving 
reduction between RIS and CLO (p=0.001), and 
between RIS and OLZ (p=0.025), in favour of CLO 
and OLZ. No significant differences were found 
between CLO and OLZ 
Mesholam-Gately 
et al. (2014) 
N=27 
Experimental 
3 months 
SCH or SAD + SUD 
CLO (n=13) or TAP (n=14) 
compared to HC 
Odour hedonic task CLO treatment is associated with broadening and 
strengthening the hedonic experience of rewarding 
olfactory stimuli and in this way, it could 
ameliorates some aspects of abnormal brain 
reward functioning in subjects with SCH + SUD 
Schnell et al(2014)  
N=30 
RCT 
12 months 
SCH + CAUD 
CLO (n=14) (50-425 mg/d, mean 
dosage 225 mg/d) or ZIP (n=16) 
(80-400 mg/d, mean dosage 200 
mg/d) 
Cannabis use (average of 
frequency use, UTS) 
Psychiatric symptoms 
(PANSS, MADS, GAF) 
Treatment compliance 
(drug plasma levels) 
Side-effects (UKU) 
Cannabis use was reduced in both groups during 
follow-up, with no significant differences between 
the two groups. CLO was associated with 
significantly fewer positive symptoms (p=0.05), but 
more side effects (p=0.017) and poorer compliance 
(p=0.024), compared to ZIP 
AD= Alcohol Dependence; AIMS= Abnormal Involuntary Movement Scale; AMS= Amisulpride; ASI= Addiction Severity Index; AUD= Alcohol Use Disorder; AUS= 
Alcohol Use Scale; BPRS= Brief Psychiatric Rating Scale; CAUD= Cannabis Use Disorder; CLO= Clozapine; CO= carbon monoxide;COA= Cocaine Abuse; COUD= 
Cocaine Use Disorder; CR= Case Report; CS= Case Series; DelD= Delusional Disorder; DUS= Drug Use Scale; FTND= Fagerstrom Test for Nicotine Dependence; 
GAF= Global Assessment of Functioning Scale; HC= Healthy controls; LAM= Lamotrigine; Long= Longitudinal; MADS= Montgomery Asberg Depression Scale; MC= 
Multicentre; Nat= Naturalistic; ND= Nicotine Dependence; N.S.= Not specified; Obs= Observational; OCDS= Obsessive Compulsive Drinking Scale; OCDUS-CAN= 
Obsessive Compulsive Drug Use Scale, cannabis version; OL= Open Label; PANSS= Positive and Negative Symptoms Scale; PDNOS= Psychotic Disorder No 
Specified; Pros= Prospective; Ret= Retrospective; RIS= Risperidone; SAD= Schizoaffective disorder; SATS= Substance Abuse Treatment Scale; SCH= 
Schizophrenia; SCHD= Schizophreniform Disorder; SU= Substance Use;SUD= Substance Use Disorder; TAP= Typical Antipsychotics; TLFB= Timeline Follow Back 
TR-SAD= Treatment Resistant Schizoaffective Disorder; TR-SCH= Treatment Resistant Schizophrenia; UKU= UKU Side Effect Rating Scale; UTS= Urine 
Toxicological Screenings; WAIS= Wechsler Adult Intelligence Scale; ZIP= Ziprasidone. 
 
A history of SUD does not appear to influence the 
response to CLO in DD patients. This fact has been 
provedin several studies. In a 6-month-follow-up 
prospective study in which 118 treatment-resistant 
patients who met DSM-III-R criteria for schizophrenia 
or SAD, 29 patients with a past or current SUD showed 
less psychopathology and better psychosocial 
functioning at baseline, and after 6 months of CLO 
therapy they had similar levels of improvement in these 
parameters compared to the group of patients without a 
history of SUD [48, 49]. In addition, in a sample of 331 
patients who suffered from schizophrenia or SAD, after 
a period of 6 months of treatment with CLO, substance 
abusers and non-substance abusers showed similar 
improvements in measures of psychopathology and 
psychosocial functioning [50]. Finally, in an open-label 
study a better response was found to CLO treatment in 
schizophrenic patients with comorbid substance abuse 
compared to non-abusing patients, in terms of a lower 
total Brief Psychiatric Rating Scale (BPRS) score, 
although readmission rates at 1-year follow-up were 
similar in both groups (23% and 21% respectively, 
p=ns) [51]. 
DISCUSSION 
To date, although DD in clinical settings is the norm 
and not the exception, there is relatively very little 
research in this field. However, among the 
pharmacological agents that have been more widely 
studied we find the group of antipsychotics. Today, 
there is a consensus on using AAP instead of TAP for 
treating patients with a SMI and a comorbid SUD. This 
is because it has been reported that patients with DD 
show a generally poorer response to treatment with 
TAP [16]. In addition, TAP has been found to be 
ineffective in terms of reducing alcohol or substance 
abuse, and they sometimes even worsen addictive 
behaviours [17]. Studies comparing TAP and AAP in 
DD patients have reported that AAP are as effective as 
TAP in treating psychiatric symptoms, but they offer 
more effectiveness in reducing substance use [52]. 
However, these results have not been always 
replicated [53].  
In regard to CLO, the data on the beneficial effect 
are consistently positive, although the lack of 
prospective, controlled, randomized trials limits the 
18    Journal of Clinical Medicine Research Updates, 2014, Vol. 1 Marín-Mayor et al. 
conclusions that can be drawn. However, clinicians are 
often hesitant to use clozapine as a first-line treatment 
due to several undesirable side effects such as the risk 
of agranulocytosis and seizures and the need for 
frequent monitoring [24]. In addition, many patients will 
not comply with the required laboratory blood tests or 
will not tolerate other common side effects of CLO such 
as hyper salivation, sedation and weight gain [46]. 
Although the mechanism by which CLO reduces 
substance abuse among patients with SMI remains 
unclear, several nonexclusive hypotheses have been 
proposed to explain the superiority of AAP over TAP in 
treating DD patients. Firstly, CLO has a unique action 
on the DA-mediated MCL system. It may reduce 
alcohol and SUD in SMI patients through its varied 
actions on multiple neurotransmitter systems, 
particularly its potent blockade of 2-NE receptors and 
increase in NE levels, its potent 5-HT2 antagonism and 
its weak blockade of D2 receptors. These actions would 
have a normalizing effect on the signal detection 
capabilities of a dysfunctional MCL brain reward 
system [6]. In addition, CLO lacks EPS and exerts a 
positive effect on psychotic positive and negative 
symptoms, relieving as well symptoms such as anxiety, 
all of which have been associated with an increase in 
substance use in DD patients as a way of “self-
medication” [5, 27, 43, 46]. In addition, CLO has been 
shown to improve some aspects of cognitive 
dysfunction associated with SMI, which are aggravated 
when a concurrent SUD is present [54]. These findings 
have led to speculation that patients taking CLO would 
have more cognitive resources to avoid substance use 
and would be more aware of their psychiatric illness 
[27]. Specifically, in regard to CLO, it has been 
suggested that the greater frequency of clinic visits 
when being treated with CLO could contribute to 
increasing abstinence [44]. Some authors have 
suggested that the superior effect of CLO in the DD 
population might have been due to a selection bias by 
which prescribers select patients for CLO treatment 
who have less severe psychotic symptoms, are more 
compliant or have a less severe SUD [45]. However, 
this hypothesis has not been confirmed by other 
authors [47]. Finally, although results are inconclusive 
and contradictory, it has been proposed that another 
pathway by which CLO could help to reduce substance 
use in the DD population is through a direct effect on 
craving reduction. This effect is thought to be due to a 
lower occupancy rate of the D2 receptor, higher 
dissociation rate of the D2 receptor and the higher 
D1/D2 receptor occupancy associated to CLO [45].  
Despite a growing body of evidence suggesting the 
beneficial effects of CLO in DD patients, interpretation 
of the published literature remains limited due to 
methodological issues that include small sample sizes, 
short follows-up, low attrition rates and the lack of 
randomized, controlled and blind methodological 
designs. This is generally due to the specific features of 
DD patients who are more difficult to engage and retain 
in trials, and associated higher rates of treatment non-
compliance.  
However, CLO may be considered as a 
pharmacological strategy in DD patients, as it covers 
both aspects of the treatment of this population. It is 
effective in reducing psychiatric symptoms and it has 
been found to be effective in reducing use of several 
substances such as nicotine, alcohol, cannabis and 
polysubstances. In addition, it has been found that a 
history of SUD does not influence the positive response 
to CLO. Although undesirable side-effects such as 
agranulocytosis and seizures have led to restriction in 
its use, generally these studies tend to find positive 
results with moderate-high doses of CLO perhaps 
increasing the risk of lack of tolerability, as CLO side 
effects are dose-dependent. This drawback can be 
solved by carefully monitoring CLO in clinical settings. 
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